Member Profile
Medigen Biotechnology Corp.
Medigen Biotechnology Corp. (MBC) was established in late 1999. The company upholds the vision of “Innovations for a better life” focusing on the development of new therapies for liver diseases and cancers. MBC has now gradually developed into a comprehensive biopharmaceutical corporation with business fields covering cell therapy technology, new drug, molecular diagnostics, precision medicine, cell-based vaccine, biologics and ophthalmic drug.
Product Pipelines
Please move your mouse cursor over abbreviations with periods to see their full names.
Company Milestones
| 2018 | Medigen collaborates with Evergreen Health Clinic and E-Da Cancer Hospital to apply for Natural Kill (NK) cell therapy treatment plan in Taiwan |
| 2019 | Medigen has entered into exclusive license agreement with Japanese publicly listed company MEDINET to expand Gamma-delta T cell therapy market in Taiwan |
| 2019 | Medigen and Cellxpert Beijing have entered into agreement under which Medigen will grant an exclusive worldwide license except Taiwan to Cellxpert for PI-88 |
| 2020 | Medigen has obtained approval from Ministry of Health and Welfare for Natural Kill (NK) cell therapy |
| 2020 | Enrollment of first patient in phase II study of combination therapy with OBP-301 and radiotherapy in Japan |
| 2020 | Medigen’s subsidiary, TBG Receives US FDA EUA for COVID-19 Nucleic Acid Test Kits |
| 2021 | Submission of IND application with the TFDA for phase 1 clinical trial of Magicell-NK |
| 2022 | Enrollment of first patient in phase I study of Magicell-NK |
| 2023 | Medigen has obtained approval from Ministry of Health and Welfare for Gamma-Delta T (GDT) cell therapy |